anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
<P>PROBLEM TO BE SOLVED: To provide a means for efficiently promoting the peeling of skin horny in a short time to improve drabness, because the sufficient peeling of the skin horny layers is difficult to cause the drabness in many cases, when the activity of a desmosome degradation enzyme on skin is deteriorated.  <P>SOLUTION: This desmosome degradation-promoting agent of the present invention is characterized by containing the extract of one or more plants selected from Zizyphus jujuba var. inermis Rehd, Saxifraga stolonifera L., and Rubus idaeus L. The external preparation for skin is characterized by containing the extract of one or more plants selected from Zizyphus jujuba var. inermis Rehd, Saxifraga stolonifera L., and Rubus idaeus L., and granules. The desmosome degradation-promoting agent has a desmosome degradation enzyme activity-promoting effect and further an excellent horny keratinocyte-removing effect, and therefore prevents the thickening of horny layer and prevents and improves the drabness of skin.  <P>COPYRIGHT: (C)2007,JPO&INPIT
Compositions, systems, and methods are described herein for the modulation, and in particular the reduction or inhibition, of expression or activity of MYC in a cell, animal or human subject. Such compositions, systems, and methods are useful to prevent, ameliorate, or treat diseases, including cell proliferation diseases and disorders such as cancer, particularly MYC-driven cancer. Compositions are described comprising a compound of formula (I), as well as pharmaceutical compositions or medicaments thereof. Also described are methods of use of such compositions to treat, prevent, or ameliorate diseases, including cell proliferation diseases and disorders such as cancer, in particular MYC-driven cancer. Compositions comprising conjugates and complexes of a compound of formula (I) are also described, which are also useful in the methods described herein. Methods are described comprising the use of a compound of formula (I), or pharmaceutical compositions thereof, for the reduction or inhibition of MYC expression or activity, and/or for achieving one or more desirable phenotypic outcomes such as, for example, decrease in cancer cell growth or proliferation, decrease in cancer cell viability, decrease in tumor volume (i.e., tumor regression), decrease in cancer metastasis, increase in animal or human survival, or other desired outcome with respect to particular phenotypes (e.g., body weight, metabolism, etc.). Related medicaments, kits, and methods of delivery of such compositions are described. Methods are also described for the development, manufacture, and/or synthesis of a compound of formula (I), as well as pharmaceutical compositions thereof. Furthermore, methods for diagnostics and testing comprising detecting MYC expression or activity levels, as well as compositions comprising kits for diagnostics and testing, are described.
The invention relates to an application of miR-26a in non-small cell lung cancer (NSCLC). MiR-26a can effectively inhibit the proliferation of NSCLC cells, and promote the apoptosis of lung cancer cells. MiRNA target gene prediction software shows that WNK3 is a potential target spot of miR-26a, the 3'-UTR area of WNK3 has two binding sites in complementary pairing with the seed sequence of miR-26a. The test shows that miR-26a can inhibit the translation and expression of target genes in the protein level. A bifluorescence reporter gene system proves the direct targeted relationship of miR-26a and WNK3. The in-depth study shows that miR-26a opens the Caspase path of cell apoptosis by targeting WNK3 protein, and finally plays the role of inducing cell apoptosis, thus providing an important therapeutic target for the accurate treatment. Through the application of miR-26a in NSCLC, an action mechanism of miR-26a is verified, potential miRNA molecules with an anti-cancer function are provided clinically, a theoretical basis is provided for the study on the relevant drug targets, and novel accurate treatment research direction and application guidance are also provided.
BACKGROUND: Pain is common in individuals with cerebral palsy (CP) and the most reported pain site is the foot/lower leg. We analyzed the prevalence of pain in the foot/lower leg and the associations with age, sex, gross motor function, and clinical findings in individuals with CP.
METHOD: This was a cross-sectional register-study, based on data reported to the Swedish Cerebral Palsy Follow-up Program (CPUP). All participants in CPUP, four years-of-age or older, were included. Pearson chi-square tests and logistic regression were used to analyze the prevalence and degree of pain in the foot/lower leg.
RESULTS: In total, 5,122 individuals were included from the CPUP database: 58% were males and 66% were under 18 years-of-age. Overall, 1,077 (21%) reported pain in the foot/lower leg. The odds ratios (ORs) of pain were higher in females (OR 1.31, 95% confidence interval (CI) 1.13-1.53), individuals who could ambulate (Gross Motor Function Classification System Level I (OR 1.84, CI 1.32-2.57) and II (OR 2.01, CI 1.46-2.79) compared to level V), and in individuals with decreased range of motion of the ankle (dorsiflexion 1-10 degrees (OR 1.43, CI 1.13-1.83) and ≤ 0 degrees (OR 1.46, CI 1.10-1.93) compared to ≥ 20 degrees). With increasing age the OR of pain increased (OR 1.02, CI 1.01-1.03) as well as the reported pain intensity (p < 0.001).
CONCLUSIONS: Pain in the foot and lower leg appears to be a significant problem in individuals with CP, particularly in those who walk. As with pain in general in this population, both pain intensity and frequency increase with age. The odds of pain in the foot and lower leg were increased in individuals with limited dorsiflexion of the ankle. Given the cross-sectional design causality cannot be inferred and it is unknown if pain causes decreased range of motion of the ankle or if decreased range of motion causes pain. Further research is needed on causal pathways and importantly on prevention.
INTRODUCTION: Standard treatment for patients with locally advanced rectal cancer (LARC) includes neoadjuvant chemoradiotherapy (nCRT) with fluoropyrimidines, followed by surgical excision. The newly introduced therapeutic strategies propose intensified regimens or more conservative approaches based on risk stratification algorithms that currently include clinicoradiological criteria but not molecular variables. How to better stratify patients is a burning clinical question, and pharmacogenomics may prove useful in identifying new genetic markers that could be incorporated into clinical algorithms to personalize nCRT. An emerging area could be the evaluation of somatic mutations as potential genetic markers that correlate with patient prognosis. Tumor mutations in the RAS/BRAF genes, as well as microsatellite instability (MSI) status, are currently used in treatment selection for colorectal cancer (CRC); however, their clinical value in LARC is still unclear.
AREA COVERED: This literature review discusses the relevant findings on the prognostic role of mutations in the key oncogenes RAS, KRAS, BRAF, PIK3CA, SMAD4 and TP53, including MSI status in LARC patients treated with nCRT.
EXPERT OPINION: KRAS proved to be the most promising marker, consistently associated with poorer disease-free survival and overall survival. Therefore, KRAS could be a good candidate for integration into the risk stratification algorithm to develop a personalized treatment.
In the first treatment cycle, the Paclitaxel dose is adapted depending on the age and the gender of the patient. In the treatment cycles 2-6 the Paclitaxel dose is adapted based on individual PK data and toxicities.
PURPOSE:To obtain a shampoo composition containing dimethylpolysiloxane, 1-hydroxy-2-pyrrolidone based compound and water soluble polymer compound, having excellent itch-preventing effect after washing of the hair and having good cleaning effect and finishing effect together. CONSTITUTION:The aimed composition containing (A) a compound expressed by formula I (n is 3-2500), (B) a compound expressed by formula II (R<1> is alkyl, alkenyl, cycloalkyl, aryl, aralkyl, etc.; R<2> is alkyl, alkenyl, halogen, phenyl, etc.; X is organic base, alkali metal ion, etc.) and/or pyrithion based compound expressed by formula III (M is polyvalent metal; m is valency of M) and (C) water soluble high polymer compound, e.g. cationic polymer compound or acrylic polymer compound at ratios of the ingredient A of 0.01-10wt.%, the ingredient B of 0.01-2wt.% and the ingredient C of 0.01-10wt.%. The aimed composition has good dispersing stability and has finishing effect enough by single washing of the hair.
Disclosed is a system and method to provide an integrated platform to automatically manage and improve patient compliance in clinical practice guidelines and protocols over a network. The system includes a common entity store and a plurality of software agents. The common entity store hosts a plurality of clinical trial data provider tenants, a tenant instance per medical indication, historical clinical trial data study, and data pertaining to a plurality of patients. Four agents interact with the common entity store to determine a plurality of actions by monitoring and reinforcing the patient compliance based on the current and historical clinical trial data. The training agent learns from the historical clinical trial data and further creates an expected reward distribution for selecting the plurality of actions from the historical clinical trial data which suggests a highest expected reward. The actions are functions of the measures such as age, gender, and concomitant medication. The RL control agent proposes compliance reinforcement message to the patient agent and the study monitor agent monitors performance measures to create a continuous process of measurement and reinforcement.
Therapeutic compsns. comprising cyclophosphamide and >=1 inorganic deriv. of Mg. The cytostatic activity of cyclophosphamide is enhanced by magnesium which plays an essential role in the synthesis of cellular components, and which is almost completely eliminated in cancerous and leukaemic cells. Particular Mg cpds. claimed are the sulphate, chloride, peroxide and nitrate.
Paraneoplastic IgA nephropathy (IgAN) is an underrecognized condition in which malignancy manifests as symptoms of IgAN, and it remains controversial regarding their mechanistic relation between IgAN and malignancy. Herein, we report a case of a 68-year-old Japanese man with glottic cancer who developed nephrotic syndrome as a clinical manifestation of IgAN. Renal biopsy revealed diffuse proliferative glomerulonephritis with glomerular capillary IgA deposition that is a rare subtype of IgAN. After complete remission of the glottic cancer by irradiation, proteinuria and hematuria disappeared. Based on his clinical course, we diagnosed paraneoplastic IgAN. Therefore, we should consider the possibility that IgAN with glomerular capillary IgA deposition might be paraneoplastic glomerulopathy especially before initiating immunosuppressive therapy. The patient thereafter developed prostate cancer and hepatocellular cancer, but IgAN did not recur. The association of IgAN specifically with the glottic cancer in this triple-cancer patient may suggest a potential link between IgAN and mucosal cancer. Because galactose-deficient IgA1 (Gd-IgA1) was observed in the similar pattern as IgA, Gd-IgA1 also may play an important role in the pathogenesis of paraneoplastic IgAN.
Acne Vulgaris (AV) is a prominent skin disease commonly affecting teenagers. It often persists into adulthood and is associated with adverse physical and psychosocial impacts. The pathophysiology of AV is conventionally correlated with 4 factors within and around the pilosebaceous unit: increased sebum production, follicular hyperkeratinization, Cutibacterium acnes proliferation, and localized immune responses. As such, conventional therapeutic approaches for AV have primarily focused on these factors. In addition to this primarily localized pathophysiology, there is a progressively emerging body of evidence indicating that underlying systemic factors contributing to a generalized immuno-inflammatory response can contribute to or exacerbate AV. In this article, we introduce and provide the supporting data, for 6 patient-centric systems that may be implicated in the development of AV: psycho-emotional stress, diet and metabolism, dysbiosis of the gut and skin microbiome, hormonal fluctuations, oxidative stress, and immune response. Identifying these pathways and their contributions in a patient-centric approach may provide expanded therapeutic opportunities for treating patients with AV. J Drugs Dermatol. 2024;23(2):90-96.   doi:10.36849/JDD.8137.
PURPOSE:To obtain a skin agent capable of making a drug readily absorbed in body and showing pharmaceutical effects of the drug without causing harmful reactions, by immobilizing an enzyme to loose keratin of skin to a sheet made of a porous material. CONSTITUTION:A skin agent obtained by immobilizing an enzyme (e.g. trypsin, pepsin or keratin hydrolase) to a sheet (e.g. polysulfone, polyacrylonitrile or cellulose derivative) preferably consisting of a porous material. Since the skin agent looses skin by the action of the immobilized enzyme, the agent makes skin into a state to permeate a drug readily. The cosmetic agent has low toxicity because the enzyme is immobilized to the sheet and absorption promoting effects continue for a long period. The amount of the enzyme immobilized is preferably 1/100-10 IU(mg) per sheet/cm<2> and the enzyme is immobilized by physical adsorption method, chemical adsorption method, covalent bond method, etc. A drug may be added to the skin agent.
Road traffic injuries (RTIs) are the largest contributor to the global trauma burden, which disproportionately affects low- and middle-income countries (LMICs). With a lack of robust emergency medical services (EMS), there has been increasing reliance on layperson bystanders to respond to RTIs in LMICs, called lay first responders (LFRs). In prospective studies of LFR activity across three sub-Saharan African countries comprising 2,039 total patient encounters, LFRs most frequently provided hemorrhage control in 61% of patient encounters. Rapid hemorrhage control for compressible extremity hemorrhage by bystander LFRs has the potential to mitigate exsanguination, reducing mortality secondary to RTIs. Rapid hemorrhage control also has applicability to high-income country settings like the United States that sustain high rates of penetrating trauma due to gun violence. Rapid hemorrhage control using tourniquets for compressible extremity hemorrhage in patients not yet in shock is strongly associated with saved lives demonstrated in battlefield studies, decreasing preventable deaths by more than 50%. Bystanders may be trained in-person or point-of-care (POC) instruction may be provided, as exists with automated external defibrillators. However, it is unknown if bystanders equipped with POC instruction are as effective as bystanders with in-person training for tourniquet application. Therefore, the investigators developed POC instructional interventions in response to the scalability challenges associated with in-person training to measure comparative effectiveness and skill retention using a randomized controlled trial design.
Sham Intermittent Hypoxia + Inspiratory threshold loading (ITL) subjects will be exposed to a single 45-minute session of sham IH (normoxia). This will consist of the subject breathing room air (FiO2=21%) through a 4 way valve connected to the hypoxicator. Exposure to normoxia will be followed by 5 sets of ITL at 80%MIP (10 breaths per set).
the investigators used data on mortality rate (per 100,000 individuals) for CVD and stroke (between 2011 and 2013, age\>35years) from the publicly available Centers for disease prevention and control (CDC) web site (www.cdc.gov). CVD mortality was defined as the number of deaths per 100,000 person-years due to circulatory causes (International Statistical Classification of Diseases, Tenth Revision, codes I00-I99). Detailed information on preparation, definition, download and sorting of data on prevalence of T2D (age-adjusted), poverty and ethnicity have been explained elsewhere. In brief, county level data on the prevalence of T2D were downloaded from the USA CDC web site (www.cdc.gov). Data on T2D was estimated using data from the CDC Behavioural Risk Factor Surveillance System (BRFSS) which is a monthly state based telephone survey of a nationally representative sample of adults aged \>20 years old. In 2012, the year for which these data were downloaded, the survey included landline telephones only and hence excluded individuals living in care homes or those without a landline telephone. More than 400,000 individuals are contacted annually to take part in the survey which has been running since 1984. Individuals are judged to have diabetes if they respond 'yes;' to the question "Has a doctor ever told participants that you have diabetes?", excluding females who indicate in a follow-up question that they only had diabetes during pregnancy. Previous work indicates that self-report of a physician's prior diagnosis of diabetes is highly reliable compared to medical records. This question does not separate those with type 1 and T2D. In the adult population of the USA more than 96% of diabetes is type 2, the investigators therefore called the estimated prevalence that of T2D. Given the magnitudes of the trends described here they cannot be attributed to differences in prevalence of the type 1 diabetes. Data on rate of mortality (per 100,000 individuals) from CVD and stroke (between 2011 and 2013, age\>35years) were also downloaded from CDC web site (www.cdc.gov, National Vital Statistics System and National Centre for Health Statistics). A previous variogram analysis has established that counties are an appropriate spatial level at which to explore the associations of factors to T2D prevalence.
Avascular necrosis (AVN) of femoral head is a progressive disease that predominantly affects younger patients. Although the exact pathophysiology of AVN has not yet to be elucidated, the disease is characterized by a vascular insult to the blood supply of the femoral head, which can lead to collapse of the femoral head and subsequent degenerative changes. Mesenchymal stem cells (MSCs) are pluripotent cells that can differentiate into multiple mesenchymal tissues, including tenocytes, chondrocytes and osteoblasts, as well as being a source of multiple growth factors to establish an environment conducive to soft and hard tissue regeneration. As bone marrow concentration has high concentration of mesenchymal stem cells, several studies have applied the autologous bone marrow concentration in halting the progression of AVN of femoral head. However, a higher level of evidence for its use on patients suffering from femoral head avascular necrosis has not been reported. This clinical trial will evaluate and compare the eligible patients who undertake core decompression surgery plus intraoperative bone marrow concentration with those who received core decompression surgery only. All patients will be followed for one year and clinical and imaging outcomes will be compared and analyzed.
The protocol phases start one day before the patient's surgery and end on the first day of mobilization after surgery. The investigator explains the protocol steps to the patient before surgery and the patient is mobilized within the first 24 hours after surgery. Perform the protocol 4 times a day and more as tolerated. Mobilization protocol: Level 1: Patient is informed about mobilization and readiness is reinforced. Level 2: Passive and active ROM movements in bed should be performed at least 3 times a day. Level 3: Head of bed \>60 degrees when the patient is sitting in bed. Duration target: 10-15 minutes. Level 4: Patient is seated on the edge of the bed. Duration target: 10-15 minutes. Level 5: The patient is helped to stand up. Level 6: First mobilization is achieved by allowing the patient to take 10-15 steps. The patient can mobilize at least 4 times a day.
Pioglitazone (Actos) is one of the most recent oral antidiabetic drugs for treating the second type of diabetes mellitus as a common chronic and lifelong disease, but with harmful side effects. The objective of this study is to evaluate the effectiveness of Artemisia annua L. extract against the Actos drug side effects in the male albino mice. In present study, the use of Actos drug alone induced hepatotoxicity, renal inflammation, hematological disorders and bladder cancer, which are manifested by biochemical abnormalities and histopathological changes, moreover, the severity of toxicity depends on its dose. In contrast, the concurrent treatment with both Actos drug (45 mg/kg) and Artemisia extract (4 g/kg) was effective against the harmful side effects of the Actos drug. Where, the biochemical, hematological and histopathological investigations showed that the hepatotoxicity, renal inflammation, hematological disorders and histopathological changes were improved using combination of Actos and Artemisia extract. In addition, the results of TNF-ɑ oncogene expression levels in bladder tissues were significantly decreased by about 99.99% using the mix of both Actos drug and Artemisia extract. In conclusion, these findings reveal that the Artemisia annua extract on TNF-ɑ oncogene expression level is very significant and effective natural product against harmful side effects of pioglitazone which associated with an increased risk of incident bladder cancer among people, but for application more studies must be achieved in that field.
PROBLEM TO BE SOLVED: To provide a material which will not deteriorate over a long period of time even if it is embedded in an organism. SOLUTION: This material is a non-biodegradation formed article constituted of crack resisting embedded prosthesis, implant or the like formed of polyolefin copolymer. The polyolefin copolymer has a principal chain in which most of polymer bonding along the copolymer chain alternates with quaternary carbon and second grade carbon. The polyolefin copolymer is a reaction product of a first rubber component containing quaternary carbon producing low-hardness polymer when it is homo-polymerized, and a second hardening component producing high-hardness polymer when it is homo-polymerized. The polyolefin copolymer, which is a reaction product of the first and second components, is elastomer and has a medium hardness between the low and high hardness. The copolymer is crack-resisting when it is embedded in vivo.
Glioblastoma (GBM) is a malignancy dominated by the infiltration of tumor-associated myeloid cells (TAMCs). Examination of TAMC metabolic phenotypes in mouse models and patients with GBM identified the de novo creatine metabolic pathway as a hallmark of TAMCs. Multi-omics analyses revealed that TAMCs surround the hypoxic peri-necrotic regions of GBM and express the creatine metabolic enzyme glycine amidinotransferase (GATM). Conversely, GBM cells located within these same regions are uniquely specific in expressing the creatine transporter (SLC6A8). We hypothesized that TAMCs provide creatine to tumors, promoting GBM progression. Isotopic tracing demonstrated that TAMC-secreted creatine is taken up by tumor cells. Creatine supplementation protected tumors from hypoxia-induced stress, which was abrogated with genetic ablation or pharmacologic inhibition of SLC6A8. Lastly, inhibition of creatine transport using the clinically relevant compound, RGX-202-01, blunted tumor growth and enhanced radiation therapy in vivo. This work highlights that myeloid-to-tumor transfer of creatine promotes tumor growth in the hypoxic niche.
A confection delivery apparatus includes a chewable set of spaced apart baffles formed from a pliable and non-resilient material. The baffles are connected perpendicular to an anchor. A joint connects to the anchor. A stem connects to the joint. The baffles curve toward the stem. The space between the baffles include a confection. An edible wax coating adheres to the baffles and the confection.